Nexium Verdict No Final Word On Pay-For-Delay

Law360, New York (December 8, 2014, 7:49 PM EST) -- A jury verdict for defendants Friday in the Nexium pay-for-delay case demonstrated the difficulty of proving that even a "large and unjustified" reverse payment slowed the launch of a generic drug, but unusual facts mean the case may not be a harbinger of how similar challenges will play out, attorneys say.

An 11-person federal jury in Boston sided with AstraZeneca PLC and Ranbaxy Inc. in the first pay-for-delay class action trial since the U.S. Supreme Court agreed the patent settlements could face antitrust scrutiny, finding that...
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.